Hair loss, restoration and graying

Pelage's October 14 announcement confirms that the first participant has been dosed in AWAKEN, the Phase 2/3 trial of topical PP405 for male androgenetic alopecia. The exact dosing date was not disclosed. This confirms trial initiation beyond the previously saved recruiting listing; it is not a new regrowth result. Pelage also forecasts a separate Phase 2 study in women with androgenetic alopecia by the end of 2026.

The original AWAKEN record lists 600 planned adult men, PP405 0.05% gel versus vehicle, with the primary change in non-vellus vertex hair count at week 24 and treatment/follow-up through week 52. Actual start is September 21, 2026; primary completion December 2027 and final completion June 2028 are registry estimates, not promised publication dates.

Limits and U.S. status: PP405 remains investigational. The sponsor repeats earlier Phase 2a findings but provides no new controlled benefit or long-term safety results here. This pattern-hair-loss program is separate from autoimmune alopecia areata. The women's start remains a sponsor forecast; no actual dosing date was verified.

Sources: Pelage October 14 AWAKEN first-dose announcement.

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (104 returned records) and all 20 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; Pelage October 14 first-dose confirmation and a separate women's Phase 2 forecast are material additions beyond the previously saved AWAKEN recruiting registry. Older Phase 2a efficacy/safety language is repeated context, not a new result.; Current manufacturer Olumiant PDF is revised October 2026 and still indicates severe alopecia areata in adults and patients aged 12 years and older. The September 25 pediatric approval is already recorded in the October 2 note; no duplicate approval finding. Adult approval dates to 2022; no ordinary androgenetic-alopecia approval was established. October warning-section revision dates were observed, but without a prior-label comparison no newly discovered risk is asserted.; BioCopper NCT07839494 October 15 update remains not yet recruiting, 88 planned; contact/instruction/eligibility edits do not establish new efficacy or a completed trial. November 2026 start and July 2027 completion remain estimates.; AWAKEN, HEADLINE, VDPHL01, GT20029, HU045 and named AA records refreshed without duplicate alerts. Complete Kintor international releases, every updated label, unregistered programs, full safety census and full audio/transcript coverage remain gaps.

Informal-source coverage: Original BQ-002 and clascoterone timing threads revisited with sponsor text. Both timing claims remain unconfirmed without a material status transition. October 14 PP405 repost is dependent on the original Pelage release; wording suggesting a final trial is not proof that all regulatory work is finished. Broad October comments repeating 2027 launch optimism are not independent confirmation. No repeat rumor alert.

Full coverage record.

Published October 2, 2026; newly appraised October 13. BRAVE-AA1/AA2 (NCT03570749/NCT03899259) adult severe-alopecia-areata follow-up concerns continued baricitinib, not pattern baldness. Among selected week 52 responders remaining on the same dose, SALT≤20 (at least 80% scalp coverage) persisted at week 200 in 115/133 (86.5%) on 4 mg and 61/72 (84.7%) on 2 mg.

The integrated safety population comprised 1303 people and 3047.73 patient-years (median 2.6, maximum 5 years). Seventy-seven experienced serious adverse events; serious infections occurred in 17, nonmelanoma skin cancer in 4, other malignancy in 7, DVT/pulmonary embolism in 2 and MACE in 1; no deaths. Serious-infection incidence was 0.5 per 100 patient-years; corresponding DVT/PE incidence 0.06.

Limits: Efficacy selects previous responders, censors after rescue/discontinuation and imputes missing values by modified last-observation-carried-forward. There is no long-term placebo comparator; these are neither all-enrollee success rates nor off-treatment cure. Uncommon events and selected trial eligibility limit generalization. U.S.: already approved severe-AA therapy; JAK boxed warnings remain. Next: real-world long-term safety and replication, undated.

Full primary paper.

Original sponsor release September 16, 2026; recovered October 13. Rubedo's index repost is dated September 29, which is not a second trial event. The company plans an RLS-1496 androgenetic-alopecia study led by David Pariser, with an October 2026 start and initial data in the first half of 2027. These are sponsor forecasts; actual recruitment/dosing, sample size, comparator, phase and a matched hair-study registry were not verified.

RLS-1496 modulates GPX4 and targets senescent/stressed-cell biology. The release's finasteride comparison concerns extracted human follicles challenged with DHT, supported by company data on file. Biopsy molecular changes and animal results do not establish visible, durable hair regrowth in patients, superiority to finasteride, or reversal of gray hair. This is pattern-hair-loss development, distinct from alopecia areata.

Safety/U.S.: Adjacent early skin trials cannot establish AGA or long-term safety; no U.S. hair-loss approval verified. The separate AK study NCT07340697 remains active/not recruiting with no posted results; it is not the promised AGA trial. Next: verify a dated protocol and actual initiation; H1 2027 is an early-data forecast, not an availability date.

Original sponsor release; separate AK registry.

Sources: rubedolife.com · source page.

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (97 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; Closed adult BRAVE-AA1/AA2 long-term paper gap and recovered RLS-1496 announced AGA trial as a new-to-watch program. AWAKEN, HEADLINE, VDPHL01, GT20029 and biological hair-graying records refreshed without new result/status alerts. Veradermics current investor news page failed; complete Kintor September 29 primary report, every international regulator/label and rare-harm census remain unappraised.

Informal-source coverage: Revisited original ToastedCaffeine BQ002 post and BioQ: candidate exists but 2027 start and candidate-specific human protocol remain unconfirmed; RLS keyword registry only returns AK, BQ002 query returns none. Cosmo July 23 still forecasts Q1 2027 U.S. filing; late 2027/2028 launch inference remains unconfirmed. PP405 community updates repeat saved recruitment. September 21 Citeline CEO episode description corroborates that RLS hair development was discussed, not patient regrowth; original audio unreviewed and secondary transcript direct fetch failed. No repeat rumor alert.

Full coverage record.

Source checked: October 9, 2026. Conference: October 8–11; Lilly's portal schedules this poster for October 8 at 5 p.m. Pacific. Actual presentation delivery was not independently verified. The downloaded poster and supplemental slides now resolve the prior numerical-data gap.

BRAVE-AA-PEDS/NCT05723198 pools adolescent cohorts. Among 96 participants originally assigned baricitinib 4 mg who had SALT ≤20 at week 52 (at most 20% scalp hair loss), 92.7% retained that threshold at week 76. Among 72 selected 4-mg “deep, multisite” responders, 95.8% maintained that stricter response; among 42 selected 2-mg deep responders, 83.3% did. Different eligibility rules for continued 2-mg and 4-mg treatment prevent a simple dose comparison. The extension uses modified last-observation-carried-forward and has no continuing randomized placebo comparison. These are maintenance rates among prior responders, not 92.7% success in everyone, off-drug durability or cure.

Safety: The 415-person all-baricitinib population supplies 615.8 patient-years, with maximum exposure 131.4 weeks; not everyone was followed 2.5 years. Seventeen participants had serious adverse events, including three serious infections; five had herpes zoster and five permanently discontinued for adverse events. One myxoid liposarcoma was judged unrelated by the investigator. No deaths or thromboembolic events were reported. The absence of a new signal does not remove boxed JAK warnings or establish rare-event safety. No confidence intervals for maintenance percentages are supplied.

U.S. status and next: The already recorded severe-AA indication from age 12 is separate from these follow-up results; pattern baldness is a different disease. Longer follow-up continues; a public release date was not verified.

Original poster and supplement; Lilly congress portal.

Original source date: September 22, 2026 registry-results posting; newly appraised October 9. This is recovered evidence, not an October trial completion.

NCT06393452 randomized 78 adults: 51 to PP405 0.05% gel and 27 to vehicle for 28 days, with follow-up to day 84. Forty-nine and 25 completed. Treatment-emergent adverse events affected 22/51 (43.1%) versus 10/27 (37.0%); these percentages are calculated from posted counts, without a comparative confidence interval. Serious events were 0/51 versus 1/27, the latter an upper-extremity fracture; there were no deaths. Twenty previous vehicle recipients entered an 84-day active open-label extension, 17 completed, and 8/20 had adverse events, with no serious events.

Interpretation: All posted primary endpoints concern safety/tolerability; secondary endpoints concern pharmacokinetics. No numerical hair-density or visible-regrowth outcome appears in the posted results. Therefore the earlier sponsor's 31% versus 0% male-subgroup response must remain a separately attributed exploratory claim with an unresolved subgroup denominator; the registry does not validate it. Small, short treatment and follow-up cannot establish long-term safety. Reported zero plasma measurements do not prove zero systemic exposure or zero risk.

U.S. status and next: Investigational. AWAKEN's October 7 registry refresh remains recruiting with 600 planned men and the previously recorded actual September 21 start; no new efficacy event. December 2027 primary and June 2028 final completion are estimates.

Original results record; AWAKEN record.

Source date: October 7, 2026 first posting. NCT07863856 at Assiut University is registered as Phase 2/3 and plans 40 men aged 18–40 with androgenetic alopecia, randomized to a single botulinum-toxin-A procedure or autologous nanofat injection. Six-month total hair-count change is primary; trichoscopic terminal/velus counts and related measures are secondary. No results are posted.

The registry is not yet recruiting, with estimated December 2026 start, August 2028 primary and October 2028 final completion. Outcome assessors are masked. Two active procedural arms without sham cannot establish efficacy over no treatment, creation of new follicles or durable visible scalp coverage. Procedural and harvesting harms require an actual safety report; no U.S. pattern-hair-loss authorization for these uses is established. Next: actual start, coherent schedule, blinded assessment details, full safety and visible benefit; no dependable release date.

Original registry.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (200 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; AWAKEN October 7 changes did not alter the saved recruitment/start/phase/size milestones, so no duplicate recruitment alert. Clascoterone, HEADLINE, VDPHL01, GT20029 and BioCopper named records retain status. Full current Kintor/Veradermics global guidance, every AA regulator/label and rare-harm census incomplete.; New Olistic retrospective female-pattern-hair-loss NCT07862374 and telogen-effluvium NCT07869199 are planned/review records without outcomes, with retrospective design but future registry schedule; not promoted as randomized benefit. FB102 October 8 celiac release is owned by autoimmune; vitiligo/AA references do not add a new hair result.

Informal-source coverage: Reopened BioQ and original ToastedCaffeine Reddit post: BQ-002 existence is corroborated, but candidate-specific human trial and 2027 start remain unconfirmed. Cosmo still forecasts Q1 2027 U.S. filing, not launch; saved late-2027/2028 community inference is unchanged. October 6 PP405 https://www.reddit.com/r/tressless/comments/1wz35hi/pp405_phase_23_study_has_begun/ repeats a saved registry milestone. October 9 pipeline hopes https://www.reddit.com/r/tressless/comments/1x1fxgm/are_you_hopeful_for_the_potential_future/ add speculative timing, not a new attributable formal event. No repeat rumor alert. Full audio/transcripts incomplete.

Full coverage record.

Source/event date: October 2, 2026. Evidence: sponsor-reported observational cross-sectional survey; full conference tables not appraised.

SCOP-GLP1 surveyed 5,804 people in France, the U.S., Mexico and Brazil: 575 GLP-1 users, 1,329 unexposed people with type 2 diabetes and/or overweight, and 3,900 reference participants without those conditions or exposure. Reported hair loss was 65.2% in GLP-1 users versus 35.3% in metabolic controls; 53.9% versus 26.5% sought hair-related care. These are self-reported proportions, not prospective adverse-event incidence. The release supplies no adjusted estimate or confidence interval and does not separate drug effects from weight loss, nutrition or group differences. Its “3.4-fold risk” wording is inconsistent with the raw prevalence ratio; no multiplier is adopted here. The sponsor markets hair-support products, and this survey does not establish their efficacy. No new regulatory action occurred. Next: original abstract/tables and prospective studies; timing unknown. Cross-link GLP-1 therapies, retaining reactive shedding separately from pattern baldness and alopecia areata.

Sponsor survey report.

Source date: October 5, 2026. Scheduled event: Fall Clinical Dermatology Conference, October 8–11 in Las Vegas.

Lilly lists a BRAVE-AA-PEDS presentation covering baricitinib efficacy through 1.5 years and safety with up to 2.5 years of treatment in adolescents with severe alopecia areata. Brittany Craiglow is the lead author. The announcement supplies no new response rates, participant disposition or comparative adverse-event counts, so this remains an upcoming evidence milestone. It concerns autoimmune alopecia areata, not androgenetic hair loss. The already recorded September U.S. indication expansion is a separate event; boxed JAK warnings and practical access remain separate from the presentation. Next: retrieve the actual poster and assess denominators, continued-treatment selection and long-term harms during/after October 8–11. No exact poster day is supplied.

October 5 official announcement.

Source/event date: 2026-10-02 registry posting. Checked: 2026-10-03. Evidence: original trial-registry status update; no efficacy results.

The current AWAKEN / NCT07819435 record lists RECRUITING, superseding the September 18 not-yet-recruiting snapshot. It records September 21, 2026 as the actual study-start date. This is a registry-reported study start, not an independently verified first-injection or first-dose announcement.

Study: Pelage’s registered Phase 2/3 randomized, masked, vehicle-controlled study plans 600 men aged 18–55 with androgenetic alopecia. PP405 0.05% gel and vehicle are compared for 24 weeks; active treatment continues through week 52, while vehicle participants are rerandomized. The primary outcome is week-24 change in non-vellus target-area hair count; visible scalp coverage and longer-term safety require separate assessment.

Interpretation and limitations: A recruitment update makes the late-stage program concrete; it supplies no new regrowth estimate or comparative safety finding. Hair counts, visible benefit, durability and creation of new follicles remain distinct. The registry’s Phase 2/3 designation must not be shortened to a completed Phase 3 result. Earlier emails, screenshots and informal recruitment dates are not retrospectively verified by this later registry update.

U.S. status: Investigational; no U.S. pattern-hair-loss marketing approval. Formal research enrollment is distinct from routine availability.

Next milestone: December 2027 primary completion; June 2028 final completion, both registry estimates. No public readout date is announced in the record.

Original study record; structured original registry.

The unchanged September 3 HEADLINE / NCT07317544 registry lists Phase 1 and Phase 2 in its structured phase field, while the official study title describes a Phase 1 first-in-human study. It remains recruiting. The previously saved June 24 sponsor report concerns early Phase 1 safety/pharmacokinetic cohorts; neither this phase-label clarification nor registration establishes Phase 2 regrowth efficacy. Retain “Phase 1 human evidence; registry lists Phase 1/2” when showing development stage. This is clarification of an existing record, not a new result or a separate medical-news alert. Original HEADLINE record; structured original registry.

Source/event date: 2026-09-30. Evidence: Sponsor-only EADV phase 2a open-label follow-up.

Q32 reported 16 weeks off treatment after SIGNAL-AA Part B (NCT06018428). Of 33 originally treated adults with severe/very severe alopecia areata, 18 entered off-drug follow-up; 44% had SALT ≤20 at week 52. Among the selected 12 with hair growth at week 36, all met the maintenance definition: less than a 20-point SALT worsening from their last on-treatment visit. This does not mean all participants maintained unchanged hair. Forty-two percent of those 12 improved further. There was no randomized off-drug comparator. The sponsor reported no serious or grade ≥3 treatment-related adverse events; injection-site reactions affected 36.3%, mostly mild. Lymphocyte reductions were observed without an infection correlation in this small dataset. These findings concern autoimmune alopecia areata, not pattern baldness, and do not establish cure or long-term safety. Bempikibart remains investigational in the U.S. Sponsor release.

Next milestone: Sponsor forecasts: regulatory discussions H2 2026; registration-directed program H1 2027; OLE data H2 2027.

Sponsor release; ClinicalTrials.gov · NCT06018428.

Source/event date: 2026-09-25. Evidence: U.S. prescribing information plus dated sponsor approval announcement.

FDA approval now includes patients aged 12 and older with severe alopecia areata. The September 2026 U.S. label confirms the expansion; the separately retrieved HTML label still displayed June and should not be used for current eligibility. BRAVE-AA-PEDS randomized 257 adolescents to placebo, 2 mg or 4 mg daily. At week 36, SALT ≤20 (at least 80% scalp coverage) occurred in 5%, 27% and 42%, respectively. Label-reported differences from placebo were 23 percentage points (95% CI 12–34) for 2 mg and 38 (26–49) for 4 mg; differences use underlying unrounded data. This is an indication expansion, not a new result for androgenetic hair loss. Boxed warnings cover serious infections, malignancy, cardiovascular events, thrombosis and mortality; efficacy does not establish risk-free long-term use. Availability through specialty pharmacies and insurance coverage are separate questions. Announcement; current PDF label, September 2026.

Next milestone: Longer-term pediatric follow-up; no new dated readout verified.

Announcement; current PDF label, September 2026.

Source date: 2026-09-24. Event date: 2026-09-24. Evidence: trial-registry registration.

A newly registered supplement trial will test biological changes in gray-hair percentage; it has not begun recruiting and has no results. NCT07839494, Mitosynergy: 88 planned adults, randomized four-arm comparison of BioCopper1, Restore Cu1, Grow + Restore Cu1 and placebo. The primary endpoint is change in gray-hair percentage measured by HairMetrix at day 168. Hair density and skin measurements are secondary outcomes. Record first posted September 24; estimated start November 2026, primary and final completion July 2027.

Limitations: Registration does not establish pigment restoration or efficacy. This is a dietary-supplement study, not a Phase 3 drug program. The title says triple-blind while structured masking fields say quadruple; no inference about completed masking or enrollment. Results must distinguish newly pigmented growth from changes in overall hair counts.

Safety: Adverse events, gastrointestinal symptoms, vital signs and laboratory changes are planned outcomes; no safety results.

U.S. status: No U.S. therapeutic approval or demonstrated hair-graying indication established by this registration.

Next milestone: Verify actual recruitment after the November 2026 estimated start; July 2027 completion is an estimate, not a release date.

Primary study record.

Related findings:

• Hair-follicle secretome presentation announced, with very early skin-recovery data.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: sponsor presentation announcement; older topline context separately labeled.

Q32 will present additional 36-week findings and initial 16-week off-drug observations from SIGNAL-AA Part B at EADV. The announcement supplies no new numerical result. Bempikibart (ADX-914) blocks IL-7 receptor-alpha signaling. NCT06018428 Part B is an open-label phase 2a cohort of 33 patients with severe or very severe autoimmune alopecia areata. Older July 13 topline context: SALT at most 20 was reached by 10/33 enrolled patients (30.3%) and 10/25 in the modified analysis (40.0%). These are not September efficacy results.

Limitations: No concurrent control in Part B; selected disease duration and small sample. Persistence off treatment does not establish cure or relevance to androgenetic hair loss. Registry estimates for June primary completion and September completion are stale; the dated conference announcement is the useful upcoming event.

Safety: July sponsor report described no serious or grade 3-or-higher treatment-related adverse events; injection-site reactions occurred in 36.3%. Longer-term and comparative safety remain uncertain.

U.S. status: Investigational, no U.S. approval.

Next milestone: Scheduled: September 30, 2026 at 15:15 CEST, EADV oral abstract LB-375, Arash Mostaghimi; poster AS-726. Sponsor plans a registration-directed program in H1 2027, a forecast.

September 21 presentation announcement; July 13 topline baseline; SIGNAL-AA registry.

Source date: 2026-09-11. Event date: 2026-09-11. Evidence: peer-reviewed randomized phase 2 study; new publication of an older completed trial.

Splitting the same daily total into two doses produced greater regrowth in a small alopecia-areata study. NCT03811912: 57 adults, 8 mg twice daily versus 16 mg once daily for 24 weeks. Mean relative SALT improvement was 46.4% (90% CI 34.3–58.4) versus 18.0% (90% CI 7.6–28.4). More twice-daily participants achieved SALT at most 20 and at most 10.

Limitations: Trial completed in November 2019 and registry results existed before this September 2026 publication; this is publication context, not a new trial or indication. No placebo arm, small sample and short follow-up. These are 90% confidence intervals.

Safety: Abstract describes mild or moderate treatment-emergent events; it cannot exclude uncommon harms or replace the approved product warnings.

U.S. status: Leqselvi is already U.S.-approved for adults with severe alopecia areata; this paper does not establish approval of a new once-daily regimen.

Next milestone: No new dated regulatory or confirmatory milestone in the paper.

Original abstract; Original DOI; Posted study and results.

Source date: 2026-09-09. Event date: 2026-09-09. Evidence: trial-registry entry; retrospectively registered study.

A formal comparison will test whether a topical scalp solution and LED cap work better together than either component alone. NCT07810504: recruiting, 40 planned women aged 35–55, four randomized arms, 24-week follow-up. KeraFactor solution versus placebo, crossed with Revian Red cap versus no cap. Hair density, diameter, spacing and terminal-to-vellus ratio are primary measurements; satisfaction and quality of life are secondary. The record reports an actual March 17, 2026 start and first posting September 9.

Limitations: Small single-center study. Device use is unblinded; solutions are blinded and assessors blinded where feasible. No results. Registration is not new evidence of synergy.

Safety: Adverse-event collection planned; none reported yet.

U.S. status: This study does not itself authorize a new combination indication or establish its efficacy.

Next milestone: Registry estimates: December 31, 2026 primary completion; January 1, 2027 final completion. No promised publication date.

Original registry.

Source date: 2026-09-15. Evidence: trial-registry update.

AWAKEN is now registered, but the latest record still says not yet recruiting. This makes Pelage’s late-stage plan more concrete without confirming first dosing. NCT07819435; Pelage; 600 planned men aged 18–55, Norwood-Hamilton IV/V. Randomized 1:1 PP405 0.05% topical gel versus vehicle for 24 weeks; active continues through week 52 while vehicle participants rerandomize. Primary endpoint: week 24 change in non-vellus target-area hair count; secondary participant-rated scalp coverage. First posted September 15, last updated September 18.

Limitations: No results. Men only and selected severity; registration does not establish efficacy or launch. Mirror dates September 30/December 31 are false precision: original gives month only.

Safety: Longer safety follow-up is planned, not observed evidence.

U.S. status: Investigational; no U.S. marketing approval.

Next milestone: September 2026 estimated start; December 2027 estimated primary completion; June 2028 estimated final completion. Public readout date unannounced.

ClinicalTrials.gov AWAKEN; Original API.

Current assessment: several programs now have randomized human results, including late-stage topical androgen blockade and extended-release oral minoxidil. Regenerative approaches remain earlier. Compare placebo-adjusted absolute hair counts and visible improvement within each trial; relative percentages across unlike studies are not a reliable ranking.

PP405 — Pelage; follicle-reactivation approach. The Phase 2a randomized vehicle-controlled study, NCT06393452, enrolled 78 men and women. The June 17, 2025 sponsor report described four weeks of dosing: in a subgroup of men with greater hair loss, 31% exceeded a 20% hair-density increase at week eight, versus none on vehicle. This is a small, short, subgroup efficacy signal, not proof of broadly durable cosmetic restoration. Pelage's March 18, 2026 update still described late-stage studies as planned for 2026. A Phase 3 launch was not verified in this check. U.S.: investigational. Initial sponsor results, 2026 sponsor update.

Clascoterone 5% solution / Breezula — Cosmo; topical androgen-receptor inhibition. SCALP1 and SCALP2 randomized 1,465 men; NCT05910450, NCT05914805. Cosmo reported positive 12-month results on April 15, 2026. The extension selected initial responders, so continued improvement there does not estimate the response rate in all users. The sponsor reported gains declining after active treatment stopped and similar tolerability to vehicle; full absolute effects and peer-reviewed analyses remain important. A focused September 13, 2026 timeline check verified Cosmo’s July 23 targets: Q1 2027 for a U.S. application and Q2 2027 for Europe. Quarter-specific sponsor guidance. Approval of the separate acne formulation does not authorize this hair-loss product. 12-month sponsor report, H1 2026 filing guidance.

VDPHL01 — Veradermics; extended-release oral minoxidil. The August 11, 2026 company filing confirms positive topline results from the randomized male Phase 2/3 Study 302 and ongoing confirmatory Phase 3 Study 304: NCT06724614, NCT06972264. The company targets male confirmatory and 12-month data in H2 2026 and female Study 306 topline in H1 2027. These remain sponsor forecasts. U.S.: investigational. Its release profile is intended to improve benefit and tolerability; a safety advantage over immediate-release minoxidil requires direct evidence. Current sponsor/SEC update, sponsor trial index.

Pyrilutamide / KX-826 — Kintor; topical androgen-receptor antagonist. A March 18, 2026 China Phase 3-stage topline announcement reports target-area non-vellus counts rising 15.33 hairs/cm² with the 1% regimen versus 4.68 with vehicle: a calculated difference of 10.65 hairs/cm². Full methods, confidence intervals and a matched registry identifier were not appraised here; the release was accessible as indexed primary-source text but failed to open directly. Keep this formulation/trial distinct from older programs and cosmetic sales. No U.S. drug approval or dependable next regulatory date was verified. Dated sponsor announcement.

GT20029 — Kintor; topical androgen-receptor protein degradation. A peer-reviewed Phase 2 study, published December 2, 2025, randomized 180 Chinese men across six regimens/control groups for 12 weeks. Two active regimens significantly outperformed their matched vehicles on non-vellus hair count; adverse events were generally mild and similar across groups. This supports further study, with limited follow-up and population breadth. Paper, NCT06692465. No current Phase 3 start or U.S. approval was substantiated in this selective search.

Established treatments and other causes. Follow material new comparative, formulation and long-term evidence for minoxidil and finasteride. FDA's 2025 alert about compounded topical finasteride highlights the need to distinguish local delivery from absent systemic risk. For severe alopecia areata, FDA-approved JAK-pathway treatments include baricitinib, ritlecitinib and deuruxolitinib; the relevant watch is durability, new populations, long-term safety and new therapies, with separate endpoints from pattern hair loss. FDA topical-finasteride alert, FDA baricitinib context, ritlecitinib evidence, deuruxolitinib evidence. Cross-link relevant immune mechanisms to autoimmune therapies.

ABS-201 — anti-prolactin-receptor antibody. Absci's June 24, 2026 interim report covers 32 adults in the single-dose part of HEADLINE, NCT07317544. Blinded, pooled safety data included no serious adverse events; five participants had mild treatment-related events. These data do not establish a safety difference versus placebo or a hair-regrowth benefit. The sponsor reported an estimated half-life of at least 65 days and initiation of multiple dosing in participants with pattern hair loss. Original sponsor report.

The current registry, last posted September 3, 2026, lists recruiting, 227 planned participants and no posted results. Its July 2028 estimated final completion differs from the sponsor's earlier interim milestones: H2 2026 proof-of-concept data and early 2027 full 26-week data. Those are forecasts, not approval dates. Updated sponsor guidance. U.S.: investigational. Track visible regrowth, durability and longer-term safety separately from hair counts and drug exposure.